New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:08 EDTEPZMEpizyme 4.492M share Secondary priced at $29.25
The deal size was increased to 4.5M shares from 4.2M shares. Citigroup, Cowen and Leerink acted as joint book running managers for the offering.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
17:25 EDTEPZMEpizyme files $250M mixed securities shelf
Subscribe for More Information
April 28, 2015
16:09 EDTEPZMEpizyme reports Q1 EPS ($1.75), may not compare to consensus (99c)
“The reacquisition of global rights to EPZ-6438 and our recent successful follow-on offering have laid the groundwork for Epizyme’s continued growth as a pioneering company in the field of epigenetic cancer therapies,” said Robert Gould, Ph.D., President and CEO, Epizyme. “We look forward to presenting updated data from the ongoing Phase 1 study of EPZ-6438 at the International Conference on Malignant Lymphoma in June. We expect to present additional data from the ongoing clinical studies of EPZ-6438 and EPZ-5676 toward the end of this year. Beyond our clinical programs, we are very pleased with the productivity of our platform, most recently evidenced by the presentations on four new HMT targets at the AACR meeting earlier this month.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use